These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7596072)

  • 1. [Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study].
    Inoue T; Ootake H; Hirano T; Tomiyoshi K; Endo K; Tanaka K; Shimizu N; Saito T
    Kaku Igaku; 1995 May; 32(5):511-21. PubMed ID: 7596072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and dosimetry of 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy.
    Bajc M; Palmer J; Ohlsson T; Edenbrandt L
    Acta Radiol; 1994 Jan; 35(1):53-7. PubMed ID: 8305273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dosimetry for indium-111-pentetreotide.
    Stabin MG; Kooij PP; Bakker WH; Inoue T; Endo K; Coveney J; de Jong R; Minegishi A
    J Nucl Med; 1997 Dec; 38(12):1919-22. PubMed ID: 9430470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
    Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.
    Forssell-Aronsson E; Bernhardt P; Nilsson O; Tisell LE; Wängberg B; Ahlman H
    Acta Oncol; 2004; 43(5):436-42. PubMed ID: 15360047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor.
    Bernhardt P; Kölby L; Johanson V; Benjegård SA; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2001 Jan; 28(1):67-73. PubMed ID: 11182566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
    Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide.
    Bass LA; Lanahan MV; Duncan JR; Erion JL; Srinivasan A; Schmidt MA; Anderson CJ
    Bioconjug Chem; 1998; 9(2):192-200. PubMed ID: 9548534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
    Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
    J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.